Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Relmada Therapeutics (NASDAQ: RLMD), a clinical-stage biotechnology company, has scheduled its first quarter 2025 financial results conference call and webcast for Monday, May 12, 2025, at 4:30 PM ET. The event will cover financial performance for Q1 ending March 31, 2025, and provide updates on recent business developments.
Investors can access the conference via US dial-in (1-877-407-0792) or International dial-in (1-201-689-8263) using conference code 13753596. A webcast replay will be available in the Investors section of Relmada's website.
Relmada Therapeutics (NASDAQ: RLMD), una società biotecnologica in fase clinica, ha programmato la conference call e il webcast per la presentazione dei risultati finanziari del primo trimestre 2025 per lunedì 12 maggio 2025 alle 16:30 ET. L'evento tratterà la performance finanziaria del primo trimestre terminato il 31 marzo 2025 e fornirà aggiornamenti sugli sviluppi recenti dell'azienda.
Gli investitori possono partecipare alla conference call tramite numero US (1-877-407-0792) o numero internazionale (1-201-689-8263) utilizzando il codice conferenza 13753596. Una replica del webcast sarà disponibile nella sezione Investitori del sito web di Relmada.
Relmada Therapeutics (NASDAQ: RLMD), una empresa biotecnológica en etapa clínica, ha programado su llamada y webcast para presentar los resultados financieros del primer trimestre de 2025 para el lunes 12 de mayo de 2025 a las 4:30 PM ET. El evento cubrirá el desempeño financiero del primer trimestre que finaliza el 31 de marzo de 2025 y ofrecerá actualizaciones sobre los desarrollos recientes del negocio.
Los inversionistas pueden acceder a la conferencia marcando desde EE.UU. (1-877-407-0792) o internacionalmente (1-201-689-8263) usando el código de conferencia 13753596. La repetición del webcast estará disponible en la sección de Inversionistas del sitio web de Relmada.
Relmada Therapeutics (NASDAQ: RLMD)는 임상 단계의 바이오테크 기업으로, 2025년 5월 12일 월요일 오후 4시 30분(동부시간)에 2025년 1분기 재무실적 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 이번 행사는 2025년 3월 31일 종료되는 1분기 재무 성과와 최근 사업 개발 현황을 다룰 예정입니다.
투자자들은 미국 내 전화번호(1-877-407-0792) 또는 국제 전화번호(1-201-689-8263)를 통해 회의 코드 13753596을 사용하여 컨퍼런스에 참여할 수 있습니다. 웹캐스트 녹화는 Relmada 웹사이트의 투자자 섹션에서 다시 볼 수 있습니다.
Relmada Therapeutics (NASDAQ : RLMD), une société biotechnologique en phase clinique, a programmé sa conférence téléphonique et son webdiffusion pour les résultats financiers du premier trimestre 2025 le lundi 12 mai 2025 à 16h30 ET. L'événement couvrira les performances financières du premier trimestre se terminant le 31 mars 2025 et fournira des mises à jour sur les récents développements commerciaux.
Les investisseurs peuvent accéder à la conférence via un numéro d'appel aux États-Unis (1-877-407-0792) ou un numéro international (1-201-689-8263) en utilisant le code de conférence 13753596. La rediffusion du webdiffusion sera disponible dans la section Investisseurs du site web de Relmada.
Relmada Therapeutics (NASDAQ: RLMD), ein biotechnologisches Unternehmen in der klinischen Phase, hat seine Telefonkonferenz und das Webcast zur Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für Montag, den 12. Mai 2025, um 16:30 Uhr ET angesetzt. Die Veranstaltung wird die finanzielle Leistung des ersten Quartals, das am 31. März 2025 endet, behandeln und Updates zu den jüngsten Geschäftsentwicklungen geben.
Investoren können über die US-Einwahlnummer (1-877-407-0792) oder die internationale Einwahlnummer (1-201-689-8263) mit dem Konferenzcode 13753596 teilnehmen. Eine Wiederholung des Webcasts wird im Investor-Bereich der Relmada-Website verfügbar sein.
- None.
- None.
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.
Conference Call and Webcast Information:
- Date: Monday, May 12, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Conference: 13753596
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.
Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational product for compulsion-related disorders including Tourette’s Syndrome and Prader-Willi Syndrome, into further studies.
For more information, visit www.relmada.com. Follow us on LinkedIn.
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
When will Relmada Therapeutics (RLMD) report Q1 2025 earnings?
How can I access Relmada Therapeutics' Q1 2025 earnings call?
Where can I find the replay of Relmada's Q1 2025 earnings webcast?
What will be discussed in Relmada Therapeutics' Q1 2025 earnings call?
